Study of the Association Between Fatigue Experienced by Patients and the Specific Side Effects of CART Cells, During the First Month After Administration for Non-Hodgkin's Lymphoma

NCT06890091 | Not Yet Recruiting

• 1 other identifier: APHP241779
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The incidence of cancer in 2023 is estimated at 433136 cases, according to INCa. Haemopathies account for 12% of these new cases of cancer cases of cancer, and around two-thirds are lymphoid haemopathies, in particular lymphomas. There are many treatments available for lymphoma. However, the arrival in France in 2018 of immunotherapy treatments such as CAR-T Cells have changed the paradigm of treatment options for certain non-Hodgkin's lymphomas. In these treatments can have both short-term and long-term adverse effects and long-term adverse effects. During hospitalisation for the administration of CAR-T Cells, acute side effects include CRS and ICANS. There is also another complication very specific to this treatment that has been observed in patients: cytopenias. This is despite the fact that one of the symptoms frequently mentioned and felt by patients during the first month after month after treatment is fatigue. Despite numerous studies on the prevalence of fatigue, healthcare professionals often underestimate this symptom. Nurses, and in particular the advanced practice nurse have a crucial role to play in assessing fatigue. The EORTC scale QLQ-FA12 is a multidimensional scale which assesses the physical emotional and cognitive dimensions of fatigue. The theory of symptom management, which was developed in 1994 by the California College of Nursing in San Francisco, is a relevant framework for understanding fatigue in patients. This theory places the patient's experience at the centre of care. This holistic approach provides a detailed framework for understanding this symptom. "According to the theoretical model, measuring the symptom is an important step and characterising it is an essential element in better targeting the actions to be taken". Although CAR-T Cell therapy is innovative and allows long-term remissions, it is important to evaluate and understand how patients live with this treatment. To our knowledge, few studies have been carried out on quality of life, particularly regarding fatigue, following the first month of CAR-T Cell administration. The research question we will address in this study is: "Is there an association between the side effects of CAR-T Cell treatment and the state of fatigue in patients receiving this treatment for non-Hodgkin's lymphoma during the first month?"

Conditions

Fatigue Symptom; Lymphoma Non-Hodgkin; Chimeric Antigen Receptor T-cell Therapy; Adverse Events

Keywords

Fatigue; CAR-T cells; Chimeric antigen receptor; Adverse events; Lymphoma Non-Hodgkin; Nurse practitionners

Outcome Measures

Primary Outcomes (1)

• Fatigue score

  European Organization for Research and Treatment of Cancer Fatigue Scale. This is a 12 items questionnaire ranging from 0 to 100. Higher scores indicate more severe fatigue. 30 days after CAR-T cell injection

  At day 30

Secondary Outcomes (21)

• Fatigue score

  At inclusion

• Fatigue score

  At day 2

• Fatigue score

  At day 10

• Fatigue score

  At day 21

• Physical Fatigue subscore

  At inclusion

Study Arms (1)

Adults receiving CAR-T Cell treatment for non-Hodgkin's lymphoma

Other: Fatigue assessment

Interventions

Fatigue assessment OTHER

Fatigue score measured by the EORTC QLQ-FA 12 fatigue self-assessment scale

Adults receiving CAR-T Cell treatment for non-Hodgkin's lymphoma

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adults receiving CAR-T Cell treatment for non-Hodgkin's lymphoma

You may qualify if:

• Adult (age\> 18year old)
• Person hospitalised for treatment with CAR-T Cells for non-Hodgkin's lymphoma.
• Person able to understand and read the French language.

You may not qualify if:

• Patient under legal protection
• Opposition to research

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead

MeSH Terms

Conditions

Fatigue; Lymphoma, Non-Hodgkin

Condition Hierarchy (Ancestors)

Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Maxime Berquier, MD

CONTACT

+33142494585; maxime.berquier@aphp.fr

Jérôme Lambert, MD PhD

CONTACT

+33 1 42 49 97 42; jerome.lambert@u-paris.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 17, 2025
• First Posted: March 21, 2025
• Study Start: April 1, 2025
• Primary Completion: May 1, 2026
• Study Completion: May 1, 2026
• Last Updated: March 21, 2025

Record last verified: 2025-03